


Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy

Supplementary Materials



Supplementary Figure S1: Kaplan-meier comparison of overall survival among ypN- patients who received different postoperative treatment.

Supplementary Table S1: The difference of incidence of chemotherapy-related adverse events ($\Delta\%$) between oxaliplatin group and 5-FU group

	Total		yPN+		yPN-	
Number of patients						
Total	763		290		473	
Aged < 73	381		144		237	
Aged \geq 73	382		146		236	
Adverse event($\Delta\%$)^a						
Acute renal failure						
Total	1.336%	$P = 0.364$	2.135%	$P = 0.400$	0.781%	$P = 0.662$
Aged < 73	-1.296%	$P = 0.428$	0.585%	$P = 0.854$	-2.548%	$P = 0.150$
Aged \geq 73	5.355%	$P = 0.035$	4.438%	$P = 0.275$	5.963%	$P = 0.068$
Infection						
Total	0.742%	$P = 0.731$	1.766%	$P = 0.543$	0.262%	$P = 0.930$
Aged < 73	0.392%	$P = 0.883$	-0.753%	$P = 0.858$	1.131%	$P = 0.743$
Aged \geq 73	2.054%	$P = 0.558$	4.438%	$P = 0.275$	0.875%	$P = 0.863$
Neutropenia						
Total	21.526%	$P < 0.001$	26.871%	$P < 0.001$	18.016%	$P < 0.001$
Aged < 73	26.104%	$P < 0.001$	32.191%	$P < 0.001$	22.333%	$P < 0.001$
Aged \geq 73	15.653%	$P < 0.001$	21.423%	$P = 0.002$	11.579%	$P = 0.019$
Nausea or vomiting						
Total	16.712%	$P < 0.001$	16.278%	$P = 0.001$	17.028%	$P < 0.001$
Aged < 73	17.096%	$P < 0.001$	20.485%	$P = 0.004$	14.785%	$P = 0.004$
Aged \geq 73	16.680%	$P < 0.001$	9.695%	$P = 0.146$	21.652%	$P = 0.001$
Dehydration						
Total	8.200%	$P = 0.002$	14.143%	$P = 0.001$	4.306%	$P = 0.192$
Aged < 73	7.430%	$P = 0.033$	13.294%	$P = 0.030$	3.583%	$P = 0.387$
Aged \geq 73	9.883%	$P = 0.016$	15.150%	$P = 0.018$	6.431%	$P = 0.225$
Diarrhea						
Total	0.869%	$P = 0.712$	4.030%	$P = 0.306$	-1.231%	$P = 0.675$
Aged < 73	-0.593%	$P = 0.856$	5.602%	$P = 0.317$	-4.578%	$P = 0.251$
Aged \geq 73	2.398%	$P = 0.489$	1.636%	$P = 0.770$	2.869%	$P = 0.515$
Fever						
Total	2.681%	$P = 0.083$	5.875%	$P = 0.016$	0.643%	$P = 0.748$
Aged < 73	5.568%	$P = 0.008$	7.441%	$P = 0.046$	4.339%	$P = 0.080$
Aged \geq 73	-0.827%	$P = 0.723$	3.571%	$P = 0.250$	-3.643%	$P = 0.265$
Anemia						
Total	2.605%	$P = 0.315$	4.416%	$P = 0.314$	1.321%	$P = 0.679$
Aged < 73	3.724%	$P = 0.342$	5.686%	$P = 0.408$	2.261%	$P = 0.630$
Aged \geq 73	-0.899%	$P = 0.787$	-0.149%	$P = 0.977$	-1.384%	$P = 0.748$
Thrombocytopenia						
Total	7.487%	$P < 0.001$	9.117%	$P < 0.001$	6.439%	$P = 0.001$
Aged < 73	5.568%	$P = 0.008$	3.595%	$P = 0.258$	6.839%	$P = 0.013$
Aged \geq 73	9.958%	$P < 0.001$	16.216%	$P < 0.001$	5.759%	$P = 0.028$

Delirium						
Total	-0.993%	<i>P</i> = 0.588	1.638%	<i>P</i> = 0.534	-2.602%	<i>P</i> = 0.295
Aged < 73	-1.880%	<i>P</i> = 0.454	-0.753%	<i>P</i> = 0.858	-2.619%	<i>P</i> = 0.402
Aged ≥ 73	-0.004%	<i>P</i> = 0.999	3.571%	<i>P</i> = 0.250	-2.137%	<i>P</i> = 0.594
IHD						
Total	0.020%	<i>P</i> = 0.986	0.626%	<i>P</i> = 0.552	-0.260%	<i>P</i> = 0.884
Aged < 73	-0.849%	<i>P</i> = 0.488	-1.087%	<i>P</i> = 0.451	-0.661%	<i>P</i> = 0.709
Aged ≥ 73	1.646%	<i>P</i> = 0.432	2.703%	<i>P</i> = 0.085	1.160%	<i>P</i> = 0.723
CHF						
Total	-0.536%	<i>P</i> = 0.674	1.381%	<i>P</i> = 0.480	-1.752%	<i>P</i> = 0.294
Aged < 73	-0.091%	<i>P</i> = 0.946	-0.251%	<i>P</i> = 0.919	-0.024%	<i>P</i> = 0.988
Aged ≥ 73	-0.483%	<i>P</i> = 0.830	3.571%	<i>P</i> = 0.250	-3.093%	<i>P</i> = 0.322
Cardiac dysrhythmia						
Total	0.624%	<i>P</i> = 0.653	3.002%	<i>P</i> = 0.124	-0.850%	<i>P</i> = 0.655
Aged < 73	-0.137%	<i>P</i> = 0.933	1.672%	<i>P</i> = 0.558	-1.298%	<i>P</i> = 0.511
Aged ≥ 73	2.058%	<i>P</i> = 0.378	4.488%	<i>P</i> = 0.096	0.611%	<i>P</i> = 0.858

Abbreviation: CHF, congestive heart failure; IHD, ischemic heart disease.

^aΔ% means the difference of incidence of chemotherapy-associated adverse events (Δ%) between oxaliplatin group and 5-FU group (Δ% = incidence of adverse events in oxaliplatin group minus incidence of adverse events in 5-FU group).